Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics by Michael E. Wechsler, Linda Rogers, G. Walter Canonica, Arnaud Bourdin, Arman Altincatal, Megan Hardin, Xavier Soler, Paul J. Rowe, Yamo Deniz, Harry Sacks, Juby A. Jacob-Nara

Get full text

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils by Eugene R. Bleecker, Reynold A. Panettieri, Njira L. Lugogo, Jonathan Corren, Nadia Daizadeh, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Angela Khodzhayev, Xavier Soler, Thomas J. Ferro, Christopher N. Hansen

Get full text

Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions by Ian D. Pavord, MD, Michael E. Wechsler, MD, William W. Busse, MD, Christian Domingo, MD, Changming Xia, PhD, Rebecca Gall, MD, Nami Pandit-Abid, PharmD, Juby A. Jacob-Nara, MD, DHSc, Amr Radwan, MBBChir, Paul J. Rowe, MD, Yamo Deniz, MD

Get full text